The Journal of Experimental Medicine
for flow cytometry > invitrogen
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 2 December 2002. doi:10.1084/jem.20020205
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 375K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grant, E. P.
Right arrow Articles by Coyle, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grant, E. P.
Right arrow Articles by Coyle, A. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2002/12/1461/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 11, December 2, 2002 1461-1471

Essential Role for the C5a Receptor in Regulating the Effector Phase of Synovial Infiltration and Joint Destruction in Experimental Arthritis

Ethan P. Grant1, Dominic Picarella1, Timothy Burwell1, Tracy Delaney1, Alisa Croci1, Nicole Avitahl1, Alison A. Humbles2, Jose-Carlos Gutierrez-Ramos1, Michael Briskin1, Craig Gerard2 and Anthony J. Coyle1

1 Millennium Pharmaceuticals, Inc., Cambridge, MA 02139
2 Ina Sue Perlmutter Laboratory, Children's Hospital, Harvard Medical School, Boston, MA 02115

Address correspondence to Ethan P. Grant, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139. Phone: 617-551-3797; Fax: 617-225-0884; E-mail: egrant{at}mpi.com; or Craig Gerard, Ina Sue Perlmutter Laboratory, Children's Hospital, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115. Phone: 617-355-6174; Fax: 617-738-1752; E-mail: Craig.Gerard{at}TCH.harvard.edu

A characteristic feature of rheumatoid arthritis is the abundance of inflammatory cells in the diseased joint. Two major components of this infiltrate are neutrophils in the synovial fluid and macrophages in the synovial tissue. These cells produce cytokines including tumor necrosis factor {alpha} and other proinflammatory mediators that likely drive the disease through its effector phases. To investigate what mechanisms underlie the recruitment of these cells into the synovial fluid and tissue, we performed expression analyses of chemoattractant receptors in a related family that includes the anaphylatoxin receptors and the formyl-MetLeuPhe receptor. We then examined the effect of targeted disruption of two abundantly expressed chemoattractant receptors, the receptors for C3a and C5a, on arthritogenesis in a mouse model of disease. We report that genetic ablation of C5a receptor expression completely protects mice from arthritis.

Key Words: arthritis • C5a receptors • granulocytes • chemoattractants • monocytes


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS